Union Korea Pharm Co., Ltd. (KOSDAQ: 080720)

Market Cap	20.13B
Revenue (ttm)	64.22B
Net Income (ttm)	-22.78B
Shares Out	7.23M
EPS (ttm)	-3,155.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	742,620
Open	3,105.00
Previous Close	3,255.00
Day's Range	2,960.00 - 3,380.00
52-Week Range	2,960.00 - 6,460.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Union Korea Pharm

Union Korea Pharm Co., Ltd. engages in the research, development, production, and sale of prescription drugs in South Korea. It offers pharmaceuticals in various formulations, including tablets, capsules, and injections in the areas of cardiovascular, gastrointestinal, muscular skeletal, antibiotics, etc. The company was formerly known as Union Pharmaceutical Co., Ltd. and changed its name to Union Korea Pharm Co., Ltd. in May 2001. Union Korea Pharm Co., Ltd. was founded in 1956 and is headquartered in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 1956
• Employees: 197
• Stock Exchange: KOSDAQ
• Ticker Symbol: 080720

Financial Performance

In 2023, Union Korea Pharm's revenue was 63.17 billion, an increase of 3.06% compared to the previous year's 61.29 billion. Losses were -18.16 billion, 1848.1% more than in 2022.